We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Nov 19
Japanese scientists first sourced halichondrin from sea sponges in 1986, and have been attempting to manufacture it for…
13 Nov 19
The EMPULSE study is a multi-centre, randomised, double-blind study to assess the oral EMPagliflozin 10mg compared to placebo
11 Nov 19
Gazyva is a monoclonal antibody designed to attach to CD20, a protein that can be observed only on…
08 Nov 19
INXN-4001 makes use of non-viral delivery of a constitutively expressed multigenic plasmid to express human S100A1, SDF-1α, and…
08 Nov 19
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated to promote erythropoiesis by increasing endogenous production of…
04 Nov 19
The results from EXCEED demonstrated a consistent and favourable safety profile for Cosentyx and no new safety signals…
30 Oct 19
The Phase III POSEIDON trial has reached a primary endpoint of statistically significant and clinically meaningful improvement in…
29 Oct 19
The clinical programme involves two studies, namely EAGLE-1, and EAGLE-2, and is conducted by the centres for disease…
15 Oct 19
Roche’s MabThera/Rituxan has secured the FDA approval in June 2018 and the European Commission approval in March 2019
14 Oct 19
JADE MONO-1 is a 12-week, double-blind, randomised parallel group study to evaluate abrocitinib 200mg, abrocitinib 100mg, or placebo